The global neurodegenerative disease market size was valued at USD 59.06 billion in 2025 and is projected to grow from USD 63.25 billion in 2026 to USD 109.50 billion by 2034, registering a CAGR of 7.1% during the forecast period from 2026 to 2034. North America dominated the neurodegenerative disease market with a market share of 42.35% in 2025.
Neurodegenerative diseases are disorders that gradually damage or destroy nerve cells in the brain and nervous system, leading to problems with memory, movement, thinking, and daily activities. Common examples include Alzheimer's disease, Parkinson's disease, and Huntington's disease. Demand for related treatments is growing due to the aging population, increasing disease prevalence, ongoing research, and the development of new diagnostic and therapeutic approaches.
Download a Free Sample To learn more about this report,
Increasing Development of Disease-Modifying Therapies
The neurodegenerative disease market is increasingly shifting toward therapies designed to target the underlying biological mechanisms of disease progression rather than focusing only on symptomatic relief. Pharmaceutical and biotechnology companies are investing in novel therapeutic approaches for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. This trend is supporting the development of treatments aimed at slowing disease progression and improving long-term patient outcomes.
In March 2025, pharmaceutical and biotechnology companies continued advancing research and development programs focused on disease-modifying therapies for neurodegenerative disorders.
Growing Adoption of Biomarker-Based Diagnosis and Patient Stratification
Biomarkers are playing an increasingly important role in the diagnosis, assessment, and management of neurodegenerative diseases. Advanced imaging, blood-based biomarkers, genetic testing, and other diagnostic approaches can support earlier disease identification and help classify patients according to specific disease characteristics. This trend is improving clinical research and supporting more precise approaches to patient selection and treatment development.
In July 2025, neuroscience researchers continued advancing biomarker-based approaches to support earlier detection, disease assessment, and patient stratification in neurodegenerative disorders.
Rising Global Aging Population and Increasing Disease Prevalence
The growing global elderly population is increasing the prevalence of age-associated neurodegenerative conditions. Disorders such as Alzheimer's disease and Parkinson's disease become more common with advancing age, creating greater demand for diagnosis, treatment, and long-term disease management. The increasing disease burden associated with population aging is therefore a fundamental driver of the neurodegenerative disease market.
In April 2025, healthcare organizations continued highlighting the increasing impact of population aging on the prevalence and management of neurodegenerative and neurological disorders.
High Cost of Advanced Therapies and Long-Term Disease Management
Neurodegenerative diseases often require prolonged medical treatment, continuous monitoring, specialized healthcare services, and long-term patient support. Advanced therapies and diagnostic procedures can also involve substantial costs, creating financial pressure on patients and healthcare systems. These affordability and resource challenges can limit access to advanced treatment options.
In June 2025, healthcare systems continued managing the financial pressures associated with providing advanced treatments and long-term care for patients with complex neurological conditions.
Expansion of Specialized Neurology Care and Treatment Infrastructure
Growing investment in specialized neurological care centers, memory clinics, research institutions, and diagnostic facilities is creating opportunities within the neurodegenerative disease market. Improved access to specialized healthcare infrastructure can support earlier diagnosis, better disease management, and wider availability of advanced treatment options. The expansion of dedicated neurology and neuroscience infrastructure therefore represents an important market opportunity.
In September 2025, healthcare organizations continued expanding specialized neurological care and diagnostic capabilities to improve services for patients with complex neurological disorders.
Complex Disease Biology and Difficulty in Clinical Drug Development
Neurodegenerative diseases involve complex biological mechanisms and can progress differently among individual patients. This variability creates difficulties in understanding disease pathways, selecting appropriate clinical trial participants, and accurately evaluating treatment effectiveness. The high complexity of disease biology and the challenges associated with successful drug development remain significant obstacles for companies operating in the neurodegenerative disease market.
In November 2025, neuroscience researchers continued focusing on improved disease models, patient stratification methods, and clinical research approaches to address the complexity of neurodegenerative drug development.
Alzheimer's Disease Segment Dominated the Market with 34.15% Share in 2025
The Alzheimer's disease segment dominated the global neurodegenerative disease market with a 34.15% share in 2025. The rising number of elderly people and the growing prevalence of Alzheimer's disease have increased the demand for early diagnosis and long-term treatment. Ongoing research and the launch of new therapies continue to strengthen the segment's leading position.
The multiple sclerosis and Parkinson's disease segments are also growing steadily. Better awareness, earlier diagnosis, and improved access to disease-modifying therapies are helping patients manage these conditions more effectively. Increasing healthcare spending and continuous research into advanced treatments are supporting growth across both segments.
The others segment is also expanding as research into rare neurodegenerative disorders continues to advance. Growing investment in neuroscience, precision medicine, and innovative drug development is expected to create new opportunities across a wider range of neurological conditions.
Request Customizationto receive a tailored report.
Immunomodulator Segment Dominated the Market with 46.8% Share in 2025
The immunomodulator segment dominated the global neurodegenerative disease market with a 46.8% share in 2025. These drugs are widely used, particularly in the treatment of multiple sclerosis, as they help regulate the immune system and slow disease progression. Their proven clinical benefits and increasing use in long-term disease management continue to drive demand.
The vesicular monoamine transporter 2 (VMAT2) and others segments are also growing steadily. VMAT2 inhibitors are increasingly used to manage movement disorders associated with neurological diseases, while the others category includes a wide range of medicines developed for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
Ongoing clinical trials, improved understanding of disease mechanisms, and the development of targeted therapies are expected to support growth across all drug categories over the forecast period.
Oral Segment Dominated the Market with 55.65% Share in 2025
The oral segment dominated the global neurodegenerative disease market with a 55.65% share in 2025. Oral medicines remain the preferred treatment option because they are easy to use, improve patient convenience, and support long-term treatment for chronic neurological disorders. Their widespread availability continues to make this the largest route of administration.
The intravenous (IV) delivery segment is growing steadily as more advanced biologic therapies and disease-modifying treatments require hospital-based administration. IV therapies are increasingly used for patients who need specialized treatment or cannot achieve the desired results with oral medicines.
The others segment also continues to expand with the development of alternative drug delivery methods, including injectable and transdermal therapies. Advances in drug delivery technologies and the introduction of innovative treatment options are expected to improve patient outcomes and support growth across all routes of administration.
Speak to an Analystto discuss market opportunities.
North America neurodegenerative disease market accounted for 42.35% of the global market, reaching USD 25.01 billion in 2025, and is projected to grow at a CAGR of 6.54% during the forecast period. The market is expanding because of the growing number of people affected by Alzheimer's, Parkinson's, and other neurological disorders. Strong healthcare infrastructure, increasing investment in neuroscience research, and the availability of advanced treatment options continue to support market growth across the region.
The U.S. market was valued at USD 21.26 billion in 2025, making it the largest contributor in North America. Rising cases of age-related neurological disorders, strong clinical research activity, and increasing adoption of innovative therapies continue to drive market growth.
Canada's market reached USD 3.75 billion in 2025. Growing healthcare spending, increasing awareness of neurological disorders, and expanding access to specialized treatments continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe neurodegenerative disease market accounted for 28.15% of the global market, reaching USD 16.63 billion in 2025, and is expected to register a CAGR of 6.31% during the forecast period. The region is seeing steady growth due to its aging population, increasing diagnosis rates, and continued investment in neurological research. Better access to healthcare services and advanced therapies is also supporting market expansion.
Germany's market accounted for USD 4.82 billion in 2025. A strong healthcare system, increasing research on neurological diseases, and growing demand for advanced treatment options continue to support market growth.
The UK market was valued at USD 3.33 billion in 2025. Rising awareness of neurological health, increasing healthcare investment, and expanding research programs continue to contribute to market growth.
Asia Pacific neurodegenerative disease market accounted for 20.45% of the global market, valued at USD 12.08 billion in 2025, and is projected to register a CAGR of 8.12% during the forecast period. A growing elderly population, improving healthcare infrastructure, and better access to neurological care are driving market growth. Governments across the region are also investing more in healthcare services and medical research.
Japan's market generated USD 2.17 billion in 2025. The country's aging population, advanced healthcare system, and strong focus on neurological research continue to support market growth.
China's market accounted for USD 6.28 billion in 2025, representing the largest share within Asia Pacific. Rising healthcare spending, a large patient population, and increasing investment in neurological disease treatment continue to drive market growth.
Latin America neurodegenerative disease market accounted for 5.25% of the global market, reaching USD 3.10 billion in 2025, and is projected to grow at a CAGR of 6.74% during the forecast period. Improving healthcare services, rising awareness of neurological disorders, and better access to diagnosis and treatment are supporting market growth across the region.
Brazil's market reached USD 1.58 billion in 2025. Growing healthcare investments, increasing diagnosis of neurological conditions, and expanding access to specialist care continue to create growth opportunities.
Middle East & Africa neurodegenerative disease market accounted for 3.8% of the global market, totaling USD 2.24 billion in 2025, and is anticipated to grow at a CAGR of 5.96% during the forecast period. Expanding healthcare infrastructure, improving neurological care services, and rising awareness of age-related diseases are supporting market growth across the region.
The UAE market was valued at USD 0.81 billion in 2025. Government investment in healthcare, increasing access to advanced neurological treatments, and growing focus on early diagnosis continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com